Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784442 | 0.89 | TAAR1 (0.60) | TAAR1LTA4HPLA2G2AMAOBKDM4E | |
| SCHEMBL14031270 | 0.89 | TSHR (0.58) | TSHRLTA4HMAOBKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL30624645 | 0.87 | TAAR1 (0.58) | TAAR1LTA4HPLA2G2AMAOBKDM4E | |
| SCHEMBL6557649 | 0.84 | MAOB (0.57) | TSHRLTA4HAPPMAOBKDM4E | |
| SCHEMBL22491568 | 0.83 | APP (0.59) | TSHRAPPMAOBKDM4E | |
| SCHEMBL26247403 | 0.83 | APP (0.64) | TSHRTAAR1LTA4HPLA2G2AAPP | |
| SCHEMBL8432804 | 0.83 | DRD4 (0.50) | TAAR1LTA4HPLA2G2AMAOBKDM4E | |
| SCHEMBL14223088 | 0.82 | DRD2 (0.48) | TAAR1LTA4HPLA2G2AAPPDRD4 | |
| SCHEMBL21100939 | 0.82 | KEAP1 (0.55) | TAAR1LTA4HPLA2G2AAPPMAOB | |
| SCHEMBL21108524 | 0.82 | DRD2 (0.48) | TAAR1LTA4HPLA2G2AAPPDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | TSHR 4013/4885TAAR1 4279/4885LTA4H 4411/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | TSHR 3954/4885TAAR1 4464/4885LTA4H 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.